Group 1 - The core viewpoint of the article is that the company, Keqian Biotechnology, has received approval from the Ministry of Agriculture and Rural Affairs for a new veterinary drug registration certificate for a vaccine aimed at preventing diseases caused by Porcine Circovirus Type 2 [1][2] - The approved product is a recombinant virus-inactivated vaccine (CH17 strain, suspension culture) specifically designed for the prevention of Porcine Circovirus Type 2 infections [1][2] - The approval will enrich the company's product line, but the market promotion and sales situation remain uncertain until the product obtains the necessary approval number for market sales [1]

Group 1 - XianDao Intelligent has set the final price for its H-share public offering at HKD 45.8 per share, with expected listing on February 11, 2026 [1] - Jida Communication is a candidate for a project with China Mobile, with an estimated service fee of approximately CNY 51.04 million [2] - Bowei Alloy's controlling shareholder plans to increase holdings by CNY 100 million to 150 million from February 10 to August 9, 2026 [3] Group 2 - Xiamen Airport reported 16,368 aircraft takeoffs and landings in January 2026, a year-on-year decrease of 4.82%, with passenger throughput of 2.38 million, down 3.84% [4] - Yitong Century has won a bid for a project worth CNY 107 million, providing comprehensive maintenance services for China Tower [5] - Huayi Brothers' controlling shareholder's 70 million shares are subject to judicial auction, representing 42.89% of his holdings and 2.52% of the company's total shares [6] Group 3 - Lianhuan Pharmaceutical received approval for the sale of Tadalafil tablets (20mg) in Ghana [7] - Aonong Biological reported a pig sales volume of 166,600 in January 2026, a year-on-year increase of 35.36% [8] - Xiantan Co. achieved chicken product sales revenue of CNY 546 million in January 2026, a year-on-year increase of 54.9% [9] Group 4 - Zhengbang Technology reported a January sales revenue of CNY 816 million from pig sales, a year-on-year increase of 19.69% [10] - Qianjin Pharmaceutical's net profit for 2025 grew by 24.74% to CNY 288 million [11] - Xinhua Pharmaceutical received a drug registration certificate for glucosamine sulfate capsules [12] Group 5 - Yuandong Bio completed the first dosing of its EP-0210 monoclonal antibody in a Phase I clinical trial for inflammatory bowel disease [13] - Jiaokong Technology signed a contract for the Sydney Metro West Line signal system subcontracting project worth AUD 93.53 million [14] - Dangsheng Technology signed a strategic cooperation framework agreement with Huineng Technology in solid-state batteries and the new energy industry [15] Group 6 - Jinhui Co. plans to acquire 100% of Fusheng Mining for CNY 210 million [16] - Cangzhou Mingzhu announced Guangzhou Light Industry as its new controlling shareholder after a share transfer [17] - Dingxin Technology's vice president was fined CNY 120,000 for short-term trading [18][19] Group 7 - China Modern Pharmaceutical's subsidiary passed a GMP compliance inspection for its production line [20] - Chaosheng Electronics plans to increase capital by CNY 400 million in its subsidiary to enhance competitiveness [21] - Lonyu Mountain reported a 25.03% year-on-year increase in pig sales revenue in January 2026 [22] Group 8 - Sanbo Brain Science's chairman has been released from investigation, and the company is operating normally [23] - Hainan Mining is planning to acquire control of Luoyang Fengrui Fluorine Industry and will resume trading on February 10, 2026 [24] - Dongwei Technology's net profit for 2025 increased by 86.81% [25] Group 9 - Yuanjie Technology plans to invest CNY 1.251 billion in a semiconductor chip and device R&D production base [26] - Metro Design signed a contract for an energy management project with Guangzhou Metro Group worth CNY 924 million [27] - Zhongmin Energy intends to acquire 51% of Fujian Yongtai Mintou Pumped Storage Co. for CNY 864 million [28] Group 10 - Dianzhi Technology plans to repurchase shares worth CNY 100 million to 200 million [29] - China Baoan was not selected as a restructuring investor for the Singshan Group [30] - Zhiguang Electric's subsidiary signed a CNY 1.004 billion contract for energy storage systems [31] Group 11 - Zhifei Biological received approval for a clinical trial of its herpes zoster vaccine [32] - KQ Bio received a new veterinary drug registration certificate for a vaccine against porcine circovirus type 2 [33] - Huanxu Electronics reported a 4% year-on-year increase in consolidated revenue for January 2026 [34] Group 12 - Xiangjia Co. reported a 10.42% year-on-year increase in live poultry sales revenue in January 2026 [35] - Kemin Foods' subsidiary reported a 68.29% year-on-year increase in pig sales revenue in January 2026 [36] - Liyuan Technology signed a procurement contract worth CNY 54.98 million [37] Group 13 - Jiuqiang Bio received a medical device registration certificate for a fibrin degradation product detection kit [38] - Zhongguancun's subsidiary passed the consistency evaluation for Tramadol Hydrochloride tablets [39] - Rundou Co. received a drug registration certificate for Candesartan Etil [40]

Core Viewpoint - The approval of the new vaccine by the Ministry of Agriculture and Rural Affairs of the People's Republic of China represents a significant milestone for the company, enhancing its product portfolio and market competitiveness [1] Group 1: Product Development - The company has received approval for its recombinant inactivated vaccine for Porcine Circovirus Type 2 (CH17 strain, suspension culture) as a new veterinary drug [1] - This approval is in accordance with the Veterinary Drug Management Regulations and the Veterinary Drug Registration Measures [1] Group 2: Business Impact - The successful approval of the vaccine will diversify the company's product offerings, promoting a multi-faceted business development strategy [1] - The new product is expected to positively influence the company's operational growth and market competitiveness [1]

Core Viewpoint - Zhongmu Co., Ltd. has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for its inactivated vaccine against Porcine Seneca Virus Disease, marking a significant advancement in the company's product offerings [1] Group 1 - The vaccine is identified as HuN-1/2017 strain and is produced through suspension culture [1] - The company has been issued a New Veterinary Drug Registration Certificate, which is a crucial step for commercialization [1]

Core Viewpoint - Zhongmu Co., Ltd. has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for its inactivated vaccine against Porcine Seneca Virus Disease (HuN-1/2017 strain) as a new veterinary drug [1] Group 1 - The vaccine has been developed in accordance with the "Veterinary Drug Management Regulations" and the "Veterinary Drug Registration Measures" [1] - The approval includes the issuance of a "New Veterinary Drug Registration Certificate" for the product [1]

Core Viewpoint - The company, Keqian Bio (688526.SH), has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for its inactivated vaccine for Seneca virus A (HB16 strain) as a new veterinary drug [1] Group 1: Company Developments - Keqian Bio has been granted a new veterinary drug registration certificate for its inactivated vaccine targeting Seneca virus A, which is significant for the company's product portfolio [1] - The approval aligns with the regulations set forth in the Veterinary Drug Administration Regulations and the Veterinary Drug Registration Measures [1] Group 2: Industry Context - Seneca virus disease, caused by Seneca virus A, primarily affects pigs and is characterized by lesions that can be confused with other diseases such as foot-and-mouth disease and vesicular stomatitis [1] - The disease has been reported in countries like Canada, Brazil, and the United States, indicating its prevalence and the potential market need for effective vaccines [1]

Core Viewpoint - The company, Keqian Bio (688526.SH), has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for its inactivated vaccine against Seneca virus disease in pigs, marking a significant advancement in veterinary medicine [1] Group 1: Company Developments - Keqian Bio has been granted a new veterinary drug registration certificate for its inactivated vaccine (HB16 strain, suspension culture) [1] - The approval is in accordance with the Veterinary Drug Administration Regulations and the Veterinary Drug Registration Measures [1] Group 2: Industry Context - Seneca virus disease, caused by Seneca virus A (SVA), is a viral infectious disease primarily affecting pigs, characterized by lesions similar to foot-and-mouth disease and other diseases [1] - The disease is transmitted mainly through contact and has been reported in countries such as Canada, Brazil, and the United States [1]